Akebia Therapeutics is a venture-backed start-up pharmaceutical company with a focus on treatments for ischemia and improvement of vascular disease. Akebia has in-licensed high-quality drug development programs and treatment assets from Procter & Gamble. The drug development programs were initiated by P&G and developed with significant investment and internal support from P&G scientists.

Caden Biosciences is a life sciences tools and services company developing assays for G-Protein Coupled Receptors (GPCRs). GPCRs have been implicated in every major disease category, and thus are the most attractive and well validated class of drug targets.

Cellectar is a radiopharmaceuticals company that designs, develops and manufactures products to detect, treat and monitor a wide variety of human cancers. Cellectar’s proprietary product candidates combine lipid-like molecules, phospholipid ethers (PLEs), with radioisotopes that destroy malignant cells. Cellectar is moving their lead molecule, CLR1404, through clinical trials.

Chromatin, Inc. is developing artificial plant chromosome technology that will enable entire chromosomes to be designed and incorporated into plant cells. Using this technology genes can be introduced in any combination or number to improve agricultural yield, or to produce novel pharmaceuticals and chemicals for industrial use.

Deltanoid Pharmaceuticals is a biopharmaceutical company engaged in research, development and commercialization of novel therapies for the treatment of human diseases. The company began operations in 2001 to advance the development of select, patented vitamin D compounds developed at the University of Wisconsin-Madison and licensed from the Wisconsin Alumni Research Foundation. Deltanoid's focus is to develop selected therapies through early phases of the drug development process and seek partners for later stage execution and commercialization.

Gala Biotech (Acquired by Cardinal Health, Inc., NYSE:CAH) has developed an innovative portfolio of proprietary protein expression technologies in mammalian cells. These systems have applications ranging from early development protein screening to large-scale pharmaceutical manufacturing.

NimbleGen Systems, Inc. (Acquired by Roche in August 2007) is the leading supplier of customized high-density microarray products and services, offering unprecedented flexibility for genomics research. NimbleGen's Maskless Array Synthesis (MAS) technology combines photo-deposition chemistry with digital light projection to shorten array fabrication from months to hours. Customers benefit from extreme flexibility, optimized array design, highly reproducible array fabrication and statistically robust results-all with low cost and quick turnaround. NimbleGen is working with scientists around the world to develop and deploy a wide range of new microarray applications.

Procertus is an oncology-based pharmaceutical company whose primary missions is to protect cancer patients against the side effects of chemotherapy and radiotherapy.

Promega is a worldwide leader in applying biochemistry and molecular biology to the development of innovative, high-value biological reagents and systems for the life sciences industry.

Third Wave Technologies (Nasdaq: TWTI) is a leader in the development and marketing of molecular diagnostics for a variety of DNA and RNA analysis applications, providing physicians and researchers with superior tools to diagnose and treat disease. Third Wave's Invader® technology provides the company's customers with exceptional accuracy, scalability and ease of use. The company offers a number of clinical products based on its Invader® technology for genetic testing related to multiple disease areas.

ZyStor Therapeutics, Inc. is a biotechnology company developing novel therapeutics with the potential to significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases (LSDs). There are more than 40 known LSDs, each caused by a deficiency in a different lysosomal enzyme. ZyStor has developed a proprietary technology, known as Glycosylation Independent Lysosomal Targeting (GILT), which can improve the delivery of therapeutics that replace the missing lysosomal enzyme in LSD patients.